Biogen asks why Ireland won’t fund new spinal muscular atrophy drug
Biogen is also urgently calling on the HSE to reform the appraisal process for orphan medicines to treat rare diseases, arguing that there is a need for a greater degree of flexibility for these assessments
Biogen Ireland has called on Minister for Health Simon Harris to explain why Ireland joined an EU pharma partnership yet remains the only country in the partnership refusing to fund Biogen’s drug.
Ireland joined the partnership, called BeNeLuxA (Belgium, Netherlands, Luxembourg, Austria) in June. It aims to jointly negotiate pharmaceutical deals.
The partnership recently reached its first collective pricing agreement on Spinraza, which is used to treat Spinal Muscular Atrophy (SMA) – a...
Subscribe from just €1 for the first month!
With any subscription you will have access to
Unlimited multi-device access to our iPad, iPhone and Android Apps
Unlimited access to our eReader library
Exclusive daily insight and opinion seven days a week
Create alerts to never miss a subject that matters to you
Get access to exclusive offers for subscribers on gifts and experiences
Get content from Business Post, Business Post Magazines, Connected, Tatler and Food & Wine
Donnelly ‘may seek legal advice’ before publishing first phase of Grace report
Phase one of the report into physical and sexual abuse of vulnerable woman is expected to be published in July
Tony O’Brien: Our kite-flying politicians haven’t yet given health workers a red cent
Promises to reward health workers for services ‘over and above the call of duty’ inevitably triggered claims from other groups that had worked through the pandemic. But there is no practical or moral equivalence to what was endured by those who kept, and keep, the health service going